Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Chew, D P
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. [electronic resource] - Circulation Feb 2001 - 961-6 p. digital
Publication Type: Journal Article; Meta-Analysis
1524-4539
10.1161/01.cir.103.7.961 doi
Abciximab
Angioplasty, Balloon, Coronary--adverse effects
Antibodies, Monoclonal--therapeutic use
Coronary Disease--complications
Demography
Diabetes Complications
Dose-Response Relationship, Drug
Drug Therapy, Combination
Hemorrhage--etiology
Heparin--adverse effects
Humans
Immunoglobulin Fab Fragments--therapeutic use
Incidence
Middle Aged
Randomized Controlled Trials as Topic--statistics & numerical data
Risk Assessment
Risk Factors
Thrombosis--etiology
Treatment Outcome
Whole Blood Coagulation Time
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. [electronic resource] - Circulation Feb 2001 - 961-6 p. digital
Publication Type: Journal Article; Meta-Analysis
1524-4539
10.1161/01.cir.103.7.961 doi
Abciximab
Angioplasty, Balloon, Coronary--adverse effects
Antibodies, Monoclonal--therapeutic use
Coronary Disease--complications
Demography
Diabetes Complications
Dose-Response Relationship, Drug
Drug Therapy, Combination
Hemorrhage--etiology
Heparin--adverse effects
Humans
Immunoglobulin Fab Fragments--therapeutic use
Incidence
Middle Aged
Randomized Controlled Trials as Topic--statistics & numerical data
Risk Assessment
Risk Factors
Thrombosis--etiology
Treatment Outcome
Whole Blood Coagulation Time